Impact of levodopainduced dyskinesias on Healthrelated Quality of Life. Results from the French COPARK study.

SANTIAGO PEREZ LLORET; LAURENCE NEGRE-PAGES; PHILIPPE DAMIER; ARNAUD DELVAL

Congreso; International Congress of Parkinson's Disease and Movement Disorders; 2017

International Parkinson and Movement Disorders Society

Objective To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson?s Disease (PD)patients and to assess the factors related to its presence.Background Levodopainduceddyskinesias (LIDs) often complicate the course of dopaminergic replacement therapy.The relative impact of LIDs and motor fluctuations has not been sufficiently explored so far.Methods 683 PD patients of the COPARK survey were evaluated. All patients were assessed in a standardizedmanner: demographics, treatments, Unified PD Rating Scale (UPDRS), and Hospital Anxiety andDepression Scale and HRQoL scales (primary outcome: PDQ39,secondary outcome: SF36).LIDs dailyduration and disability were obtained from UPDRS IV items #32 and #33. Daily duration of wearingoffwas obtained from UPDRS IV item #36 and disability was calculated as UPDRS II in OFFminusONstate.Ttestwas employed to compare HRQoL scores between PD patients with or without LIDs.Multivariate testing was performed by logistic regression. The relative contribution of LIDs or wearingoffduration and disability to HRQoL scores was modelled by ANOVA, with eta2 scores representing the effectsize of each analyzed factor.Results 183 PD patients (26.8%) suffered from LIDs. Significant differences between patients with or without LIDswere detected in PDQ39total score (33.1±1.1 vs 45.4±2.1, p